Skip to main content
PMC home page
Journal of the Royal Society of Medicine logoLink to Journal of the Royal Society of Medicine
. 1985 Oct;78(10):797–799. doi: 10.1177/014107688507801001

Endocrine treatment of prostatic cancer.

G Williams
PMCID: PMC1289941  PMID: 4045880

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Auf G., Ghanadian R. Analysis of androgen receptors in the human prostate by isoelectric focussing in polyacrylamide gel. J Steroid Biochem. 1981 Dec;14(12):1261–1267. doi: 10.1016/0022-4731(81)90330-7. [DOI] [PubMed] [Google Scholar]
  2. Blackard C. E. The Veterans' Administration Cooperative Urological Research Group studies of carcinoma of the prostate: a review. Cancer Chemother Rep. 1975 Jan-Feb;59(1):225–227. [PubMed] [Google Scholar]
  3. Concolino G., Marocchi A., Margiotta G., Conti C., Di Silverio F., Tenaglia R., Ferraro F., Bracci U. Steroid receptors and hormone responsiveness of human prostatic carcinoma. Prostate. 1982;3(5):475–482. doi: 10.1002/pros.2990030506. [DOI] [PubMed] [Google Scholar]
  4. Coune A., Smith P. Clinical trial of 2-bromo-alpha-ergocryptine (NSC-169774) in human prostatic cancer. Cancer Chemother Rep. 1975 Jan-Feb;59(1):209–213. [PubMed] [Google Scholar]
  5. Denis L., Declercq G. Anti-estrogens in the treatment of prostatic cancer. Acta Urol Belg. 1980 Jan;48(1):106–109. [PubMed] [Google Scholar]
  6. Geller J., Albert J., Yen S. S., Geller S., Loza D. Medical castration with megestrol acetate and minidose of diethylstilbestrol. Urology. 1981 Apr;17(4 Suppl):27–33. [PubMed] [Google Scholar]
  7. Geller J., Albert J., Yen S. S. Treatment of advanced cancer of prostate with megestrol acetate. Urology. 1978 Nov;12(5):537–541. doi: 10.1016/0090-4295(78)90467-3. [DOI] [PubMed] [Google Scholar]
  8. Ghanadian R., Auf G., Williams G., Davis A., Richards B. Predicting the response of prostatic carcinoma to endocrine therapy. Lancet. 1981 Dec 19;2(8260-61):1418–1418. doi: 10.1016/s0140-6736(81)92829-4. [DOI] [PubMed] [Google Scholar]
  9. Huggins C., Scott W. W. Bilateral Adrenalectomy in Prostatic Cancer: Clinical Features and Urinary Excretion of 17-Ketosteroids and Estrogen. Ann Surg. 1945 Dec;122(6):1031–1041. [PMC free article] [PubMed] [Google Scholar]
  10. Jacobo E., Schmidt J. D., Weinstein S. H., Flocks R. H. Comparison of flutamide (SCH-13521) and diethylstilbestrol in untreated advanced prostatic cancer. Urology. 1976 Sep;8(3):231–233. doi: 10.1016/0090-4295(76)90373-3. [DOI] [PubMed] [Google Scholar]
  11. Kerle D., Williams G., Ware H., Bloom S. R. Failure of long term luteinising hormone releasing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone. Br Med J (Clin Res Ed) 1984 Aug 25;289(6443):468–469. doi: 10.1136/bmj.289.6443.468. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Pontes J. E., Karr J. P., Kirdani R. Y., Murphy G. P., Sandberg A. A. Estrogen receptors and clinical correlations with human prostatic disease. Urology. 1982 Apr;19(4):399–403. doi: 10.1016/0090-4295(82)90197-2. [DOI] [PubMed] [Google Scholar]
  13. Reiner W. G., Scott W. W., Eggleston J. C., Walsh P. C. Long-term survival after hormonal therapy for stage D prostatic cancer. J Urol. 1979 Aug;122(2):183–184. [PubMed] [Google Scholar]
  14. Schally A. V., Arimura A., Baba Y., Nair R. M., Matsuo H., Redding T. W., Debeljuk L. Isolation and properties of the FSH and LH-releasing hormone. Biochem Biophys Res Commun. 1971 Apr 16;43(2):393–399. doi: 10.1016/0006-291x(71)90766-2. [DOI] [PubMed] [Google Scholar]
  15. Trachtenberg J., Pont A. Ketoconazole therapy for advanced prostate cancer. Lancet. 1984 Aug 25;2(8400):433–435. doi: 10.1016/s0140-6736(84)92909-x. [DOI] [PubMed] [Google Scholar]
  16. Trachtenberg J. The treatment of metastatic prostatic cancer with a potent luteinizing hormone releasing hormone analogue. J Urol. 1983 Jun;129(6):1149–1152. doi: 10.1016/s0022-5347(17)52615-4. [DOI] [PubMed] [Google Scholar]
  17. Trachtenberg J., Walsh P. C. Correlation of prostatic nuclear androgen receptor content with duration of response and survival following hormonal therapy in advanced prostatic cancer. J Urol. 1982 Mar;127(3):466–471. doi: 10.1016/s0022-5347(17)53868-9. [DOI] [PubMed] [Google Scholar]
  18. Walsh P. C. Physiologic basis for hormonal theapy in carcinoma of the prostate. Urol Clin North Am. 1975 Feb;2(1):125–140. [PubMed] [Google Scholar]
  19. Williams G., Kerle D., Griffin S., Dunlop H., Bloom S. R. Biodegradable polymer luteinising hormone releasing hormone analogue for prostatic cancer: use of a new peptide delivery system. Br Med J (Clin Res Ed) 1984 Dec 8;289(6458):1580–1581. doi: 10.1136/bmj.289.6458.1580. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press

RESOURCES